drugset / Trial / NCT01071057

Naloxone for the Treatment of Opioid-Induced Pruritus

NCT01071057

Phase 2/3 Completed 92 enrolled University of British Columbia
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to improve how we treat itching, a common side effect associated with the use of morphine pain medication. Itching is a problem experienced by up to 30% of the children treated with pain medications in the morphine family. Despite studies demonstrating the effectiveness of using naloxone to treat itchiness in adults receiving morphine pain medications, there are not many studies in children. This study is designed to study how well naloxone works for treatment of itching in children

Timeline

Start
2010-12
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxone Small molecule 12 ug/ml Intravenous
Comparator Naloxone Small molecule 20 ug/kg Intravenous
Comparator Morphine Other / unclassified 1 mg/ml Intravenous

Indications

No indication recorded.